News brief­ing: In­cyte bankrolls an ear­ly-stage myelofi­bro­sis pair-up with Jakafi; In­no­Care gets Chi­nese ap­proval for lead drug

Look­ing to fur­ther bol­ster its block­buster fran­chise for Jakafi, In­cyte has struck a deal to part­ner up on a new com­bi­na­tion ap­proach to treat­ing myelofi­bro­sis.

In­cyte is bankrolling a Phase Ib study com­bin­ing Jakafi with CK0804, Cel­lenkos’ “cry­op­re­served CX­CR4 en­riched, al­lo­gene­ic, um­bil­i­cal cord blood-de­rived T-reg­u­la­to­ry cells.” The small­er biotech will car­ry out the study, leav­ing In­cyte with an op­tion to swoop in and pick up sole de­vel­op­ment and com­mer­cial­iza­tion rights — if it all works out.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER